Skip to main content

Cabaletta Bio, Inc.

CABA
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001759138

No open-market purchases or sales by Cabaletta Bio, Inc. insiders were filed in the last 90 days; 139 institutions reported holding it in 13F filings for Q2 2026, worth $492.9M in total; no superinvestor holds it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Cabaletta Bio, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
0 filings
Insiders trading
0
Net value
$0
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Cabaletta Bio, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Cabaletta Bio, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Henriques Richard C JrDirector–Jun 10, 20261
Simon MarkDirector147,205Jun 10, 20262
Tomasello ShawnDirector22,725IndirectJun 10, 20262
Bollard CatherineDirector5,405Jun 10, 20262
Brun Scott C.Director–Jun 10, 20261
Nichtberger StevenPresident & CEO1,031,483Mar 2, 20262
Marda AnupChief Financial Officer50,000Mar 2, 20261
Chang David J.Chief Medical Officer8,800Mar 2, 20262
Binder GwendolynPresident, Science & Tech.31,312Mar 2, 20262
Gerard MichaelGeneral Counsel6,600Mar 2, 20262
Das ArunChief Business Officer–Mar 2, 20261
Gavel SteveChief Commercial Officer22,170Jan 21, 20262
Rocklage Scott M10% Owner333,144IndirectNov 3, 20210
Schwab Andrew J.10% Owner333,144IndirectNov 3, 20210
Parmar Kush10% Owner333,144IndirectNov 3, 20210
5AM Ventures V, L.P.10% Owner333,144IndirectNov 3, 20210
5AM Opportunities I, L.P.10% Owner333,144IndirectNov 3, 20210
5AM Opportunities I (GP), LLC10% Owner333,144IndirectNov 3, 20210
5AM Partners V, LLC10% Owner333,144IndirectNov 3, 20210

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Jan 21, 2026 (view filing)Jan 21Same dayChang David J.Chief Medical OfficerPPurchase+8.80K$2.26+$19.9KNew position8.80K after
Jan 21, 2026 (view filing)Jan 21Same dayBinder GwendolynPresident, Science & Tech.PPurchase+11.3K$2.19+$24.8K+56.6%31.3K after
Jan 21, 2026 (view filing)Jan 21Same dayTomasello ShawnDirectorPPurchase+22.7K$2.21+$50.2KNew position22.7K after
Jan 21, 2026 (view filing)Jan 21Same dayGavel SteveChief Commercial OfficerPPurchase+22.2K$2.27+$50.3KNew position22.2K after
Jan 21, 2026 (view filing)Jan 21Same dayBollard CatherineDirectorPPurchase+4.41K$2.27+$10.0K+440.5%5.41K after
Jan 21, 2026 (view filing)Jan 21Same dayNichtberger StevenPresident & CEOPPurchase+45.0K$2.24+$100.8K+4.6%1.03M after
Jan 21, 2026 (view filing)Jan 21Same daySimon MarkDirectorPPurchase+11.1K$2.28+$25.2K+8.1%147.2K after
Jan 21, 2026 (view filing)Jan 21Same dayGerard MichaelGeneral CounselPPurchase+6.60K$2.27+$15.0KNew position6.60K after
Jan 19, 2024 (view filing)Jan 19Same dayBinder GwendolynSee RemarksSSale−11.0K$19.59−$215.5K−35.5%20.0K after2 lots
Dec 19, 2023 (view filing)Dec 19Same dayBinder GwendolynSee RemarksSSale−11.0K$21.89−$240.8K−35.5%20.0K after2 lots
Nov 21, 2023 (view filing)Nov 201 dayBinder GwendolynSee RemarksSSale−11.0K$17.82−$196.0K−35.5%20.0K after2 lots
Oct 19, 2023 (view filing)Oct 19Same dayBinder GwendolynSee RemarksSSale−11.0K$13.36−$146.9K−35.5%20.0K after2 lots
Sep 20, 2023 (view filing)Sep 191 dayBinder GwendolynSee RemarksSSale−11.0K$17.56−$193.2K−35.5%20.0K after2 lots10b5-1
Aug 22, 2023 (view filing)Aug 211 dayBinder GwendolynSee RemarksSSale−11.0K$13.42−$147.6K−35.5%20.0K after2 lots10b5-1
Jul 19, 2023 (view filing)Jul 19Same dayBinder GwendolynSee RemarksSSale−11.0K$13.82−$152.0K−35.5%20.0K after2 lots10b5-1
Jun 21, 2023 (view filing)Jun 201 dayBinder GwendolynSee RemarksSSale−11.0K$12.99−$142.9K−35.5%20.0K after10b5-1
May 19, 2023 (view filing)May 19Same dayBinder GwendolynSee RemarksSSale−22.0K$11.81−$259.8K−52.4%20.0K after10b5-1
Oct 19, 2022 (view filing)Oct 19Same dayNichtberger StevenPresident & CEOPPurchase+8.13K$1.25+$10.2K+0.8%986.5K after
Oct 18, 2022 (view filing)Oct 18Same dayBollard CatherineDirectorPPurchase+1.00K$0.99+$990New position1.00K after
Oct 18, 2022 (view filing)Oct 18Same dayMarda AnupChief Financial OfficerPPurchase+50.0K$0.99+$49.5KNew position50.0K after
Oct 18, 2022 (view filing)Oct 18Same daySimon MarkDirectorPPurchase+118.0K$0.98+$115.6K+650.4%136.1K after
Oct 18, 2022 (view filing)Oct 18Same daySimon MarkDirectorPPurchase+7.00K$0.98+$6.86KNew position7.00K after
Oct 18, 2022 (view filing)Oct 18Same dayBinder GwendolynSee RemarksPPurchase+20.0K$0.99+$19.8KNew position20.0K after
Oct 18, 2022 (view filing)Oct 18Same dayNichtberger StevenPresident & CEOPPurchase+141.9K$0.99+$140.5K+17.0%978.4K after
Nov 3, 2021 (view filing)4:38 PM ETNov 12 daysRocklage Scott M and 6 others10% OwnerSSale−295.0K$13.00−$3.83M−47.0%333.1K after2 lots
Sep 9, 2021 (view filing)5:34 PM ETSep 72 daysRocklage Scott M and 6 others10% OwnerSSale−625.0K$9.70−$6.06M−23.9%1.99M after